Open access

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Rachel E Sanborn, Omid Hamid, Elisabeth GE de Vries, Patrick A Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A Autio, Daniel C Cho, Ruth Plummer, Mark Stroh, Lawrence Lu, Fiona Thistlethwaite

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002446; DOI: 10.1136/jitc-2021-002446
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
Gabrielle Leclercq, Hélène Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch, Antje-Christine Walz, Vesna Pulko, Johannes Sam, John Challier, Cristiano Ferlini, Alex Odermatt, Pablo Umaña, Marina Bacac, Christian Klein

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002582; DOI: 10.1136/jitc-2021-002582
Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma
Nurulhuda Mustafa, Adina Huey Fang Nee, Jing Yuan Chooi, Sabrina Hui Min Toh, Tae-Hoon Chung, Viknesvaran Selvarajan, Shuangyi Fan, Siok Bian Ng, Michelle Poon, Esther Chan, Joanne Lee, Yen Lin Chee, Anand D Jeyasekharan, Longen Zhou, Jennifer Yang, Wee Joo Chng

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002123; DOI: 10.1136/jitc-2020-002123
Recombinant Mycobacterium smegmatis delivering a fusion protein of human macrophage migration inhibitory factor (MIF) and IL-7 exerts an anticancer effect by inducing an immune response against MIF in a tumor-bearing mouse model
Hyein Jeong, So-Young Lee, Hyejun Seo, Bum-Joon Kim

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003180; DOI: 10.1136/jitc-2021-003180
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab
Sang T. Kim, Jean Tayar, Siqing Fu, Danxia Ke, Elliot Norry, Amy Sun, Juli Miller, David S. Hong

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002716; DOI: 10.1136/jitc-2021-002716
Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) 1; DOI: 10.1136/jitc-2019-000218corr1
Correction: Mesenchymal stem cells and oncolytic viruses: joining forces against cancer
Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) 1; DOI: 10.1136/jitc-2020-001684corr1
Correction: Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) 1; DOI: 10.1136/jitc-2020-001498corr1
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
David G DeNardo, Anna Galkin, Jakob Dupont, Lei Zhou, Johanna Bendell

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003005; DOI: 10.1136/jitc-2021-003005
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
Peixin Chen, Lishu Zhao, Hao Wang, Liping Zhang, Wei Zhang, Jun Zhu, Jia Yu, Sha Zhao, Wei Li, Chenglong Sun, Chunyan Wu, Yayi He, Caicun Zhou

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002554; DOI: 10.1136/jitc-2021-002554

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages